| Target Price | $52.02 |
| Price | $48.72 |
| Potential |
6.77%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target Bristol-Myers Squibb 2026 .
The average Bristol-Myers Squibb target price is $52.02.
This is
6.77%
register free of charge
$71.40
46.55%
register free of charge
$33.43
31.38%
register free of charge
|
|
| A rating was issued by 33 analysts: 11 Analysts recommend Bristol-Myers Squibb to buy, 20 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bristol-Myers Squibb stock has an average upside potential 2026 of
6.77%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 48.30 | 48.16 |
| 7.32% | 0.30% | |
| EBITDA Margin | 42.27% | 36.44% |
| 4.43% | 13.79% | |
| Net Margin | -18.53% | 27.60% |
| 203.90% | 248.98% |
28 Analysts have issued a sales forecast Bristol-Myers Squibb 2025 . The average Bristol-Myers Squibb sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Bristol-Myers Squibb EBITDA forecast 2025. The average Bristol-Myers Squibb EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 Bristol-Myers Squibb Analysts have issued a net profit forecast 2025. The average Bristol-Myers Squibb net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.41 | 6.53 |
| 214.25% | 248.07% | |
| P/E | 7.24 | |
| EV/Sales | 2.67 |
28 Analysts have issued a Bristol-Myers Squibb forecast for earnings per share. The average Bristol-Myers Squibb EPS is
This results in the following potential growth metrics and future valuations:
Bristol-Myers Squibb...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Apr 23 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Apr 22 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 10 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 23 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Apr 23 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Apr 22 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


